Navana Pharmaceuticals PLC (DSE:NAVANAPHAR)
Bangladesh
· Delayed Price · Currency is BDT 58.30
-0.50 (-0.85%)
At close: Apr 28, 2026
Navana Pharmaceuticals Revenue
Navana Pharmaceuticals had revenue of 2.78B BDT in the quarter ending December 31, 2025, with 24.83% growth. This brings the company's revenue in the last twelve months to 10.07B, up 26.26% year-over-year. In the fiscal year ending June 30, 2025, Navana Pharmaceuticals had annual revenue of 8.84B with 28.19% growth.
Revenue (ttm)
10.07B
Revenue Growth
+26.26%
P/S Ratio
0.62
Revenue / Employee
2.10M
Employees
4,798
Market Cap
6.26B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orion Pharma | 3.12B |
| Techno Drugs | 3.15B |
| The IBN SINA Pharmaceutical Industry | 13.42B |
| Asiatic Laboratories | 2.24B |
| The ACME Laboratories | 38.86B |
| Ambee Pharmaceuticals | 183.57M |
| Beacon Pharmaceuticals | 14.78B |
| Pharma Aids | 474.48M |